Pluripotent stem cell-derived retinal organoid/cells for retinal regeneration therapies: A review.
ESC
ESC, embryonic stem cell
LGIR, lymphocyte graft immune reaction
MEA, multiple electrode array
MHC, major histocompatibility complex
OCT, optical coherent tomography
ONL, outer nuclear layer
RGC, retinal ganglion cell
RP, retinitis pigmentosa
Retinal degeneration
Retinal organoids
Retinal regeneration
Transplantation
iPSC
iPSC, induced pluripotent stem cell
Journal
Regenerative therapy
ISSN: 2352-3204
Titre abrégé: Regen Ther
Pays: Netherlands
ID NLM: 101709085
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
29
10
2022
revised:
28
11
2022
accepted:
13
12
2022
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
In recent decades, many researchers have attempted to restore vision via transplantation of retina/retinal cells in eyes with retinal degeneration. The advent of induced pluripotent stem cells (iPSC) and retinal organoid induction technologies has boosted research on retinal regeneration therapy. Although the recognition of functional integration of graft photoreceptor cells in the host retina from 2006 has been disputed a decade later by the newly evidenced phenomenon denoted as "material transfer," several reports support possible reconstruction of the host-graft network in the retinas of both end-stage degeneration and in progressing degeneration cases. Based on proof of concept (POC) studies in animal models, a clinical study was conducted in Kobe, Japan in 2020 and showed the feasibility of cell-based therapy using iPSC retinal organoid technology. Although the graft potency of human embryonic stem (ES)/iPS cell-derived retinal organoid/retinal cells has been suggested by previous studies, much is still unknown regarding host capability, that is, how long-standing human degenerating retinas are capable of rewiring with transplanted cells. This review summarizes past POC studies on photoreceptor replacement therapy and introduces some new challenges to maximize the possible efficacy in future human clinical studies of regenerative therapy.
Identifiants
pubmed: 36712956
doi: 10.1016/j.reth.2022.12.005
pii: S2352-3204(22)00127-4
pmc: PMC9841126
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
59-67Informations de copyright
© 2022 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
Déclaration de conflit d'intérêts
Our researches conducted at RIKEN BDR and Kobe City Eye Hospital introduced in this review were funded by 10.13039/100009619AMED, Japan (JP17bm0204002, JP20bm0204002, JP19bk0104082) and by Japanese ministry of education (JSPS KAKENHI Grant 15K10913, 19K09942) and Sumitomo Pharma. Co. Ltd.
Références
Cell Stem Cell. 2012 Jun 14;10(6):771-785
pubmed: 22704518
Stem Cell Reports. 2018 Sep 11;11(3):665-680
pubmed: 30100409
Stem Cell Reports. 2022 Nov 8;17(11):2392-2408
pubmed: 36306783
Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):E81-90
pubmed: 26699487
Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):1101-6
pubmed: 23288902
iScience. 2021 Jul 16;24(8):102866
pubmed: 34409267
Nature. 2011 Apr 7;472(7341):51-6
pubmed: 21475194
Mol Ther. 2017 Sep 6;25(9):1999-2013
pubmed: 28619647
Invest Ophthalmol Vis Sci. 1994 Jul;35(8):3145-53
pubmed: 8045709
Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8518-23
pubmed: 24912154
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Stem Cell Reports. 2016 Oct 11;7(4):635-648
pubmed: 27641649
Nat Med. 2021 Jul;27(7):1223-1229
pubmed: 34031601
Nature. 2012 May 3;485(7396):99-103
pubmed: 22522934
Stem Cell Reports. 2018 Mar 13;10(3):1059-1074
pubmed: 29503091
Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5411-8
pubmed: 19515998
Transl Vis Sci Technol. 2021 Sep 1;10(11):17
pubmed: 34559184
Cell. 2015 May 7;161(4):817-32
pubmed: 25957687
Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1686-95
pubmed: 12657610
Nat Rev Immunol. 2003 Nov;3(11):879-89
pubmed: 14668804
Nat Commun. 2016 Nov 30;7:13537
pubmed: 27901042
Stem Cell Reports. 2020 Aug 11;15(2):482-497
pubmed: 32707075
Nat Commun. 2016 Oct 04;7:13028
pubmed: 27701381
Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2586-2603
pubmed: 29847666
Nature. 2006 Nov 9;444(7116):203-7
pubmed: 17093405
Front Cell Neurosci. 2019 Sep 18;13:423
pubmed: 31619966
Prog Retin Eye Res. 2011 Mar;30(2):115-28
pubmed: 21111842
Stem Cell Reports. 2017 Jan 10;8(1):69-83
pubmed: 28076757
Opt Lett. 2019 Dec 1;44(23):5671-5674
pubmed: 31774751
Am J Ophthalmol. 2008 Aug;146(2):172-182
pubmed: 18547537
J Neurosci. 2012 Aug 1;32(31):10713-24
pubmed: 22855819
Nat Commun. 2019 Oct 4;10(1):4524
pubmed: 31586094
Nat Commun. 2016 Oct 04;7:13029
pubmed: 27701378
Sci Rep. 2016 Jul 13;6:29784
pubmed: 27405580
Nat Commun. 2014 Jun 10;5:4047
pubmed: 24915161
Lancet. 2017 Aug 26;390(10097):849-860
pubmed: 28712537
J Clin Invest. 2022 Jun 15;132(12):
pubmed: 35482419
Stem Cells. 2011 Aug;29(8):1206-18
pubmed: 21678528
Cell Rep. 2021 Apr 20;35(3):109022
pubmed: 33882303
Neurochem Int. 2009 Mar-Apr;54(3-4):143-60
pubmed: 19114072
iScience. 2021 Dec 20;25(1):103657
pubmed: 35024589
EBioMedicine. 2019 Jan;39:562-574
pubmed: 30502055
Stem Cell Reports. 2014 Apr 24;2(5):662-74
pubmed: 24936453
Cell Stem Cell. 2022 Mar 3;29(3):460-471.e3
pubmed: 35104442
Invest Ophthalmol Vis Sci. 2014 Jun 06;55(7):4244-51
pubmed: 24906859
Prog Retin Eye Res. 2022 Mar;87:101000
pubmed: 34464742
Exp Neurol. 1999 May;157(1):58-68
pubmed: 10222108
Prog Retin Eye Res. 2004 Sep;23(5):475-94
pubmed: 15302347
Stem Cell Reports. 2021 Apr 13;16(4):851-867
pubmed: 33770500